Piper Sandler cuts Nyxoah stock price target on balance sheet concerns

Nyxoah reported first-quarter net revenue of €6.4 million, ahead of Piper Sandler’s €5.9 million estimate and the Street’s €6.1 million forecast, and guided fiscal 2026 revenue to €36 million-€40 million versus Piper Sandler’s prior €30.4 million estimate. U.S. Genio revenue rose 25% quarter-over-quarter, with 91 active U.S. accounts and 241 prior authorizations heading into Q2. Piper Sandler cut its price target to $7 from $9 but kept an Overweight rating, while Stifel downgraded the shares to Hold and Cantor Fitzgerald reiterated Overweight with an $11 target.

Analysis

The key takeaway is not the near-term revenue beat; it is that Nyxoah is still in the classic commercialization trap where demand is improving faster than the business model can self-fund. In medtech, early U.S. traction often looks statistically encouraging right before capital markets reprice the balance-sheet risk, because reimbursement conversion and account activation create working-capital drag before operating leverage shows up. That means the stock can respond positively to adoption metrics while still being fundamentally hostage to financing terms over the next 2-3 quarters.

The second-order winner here is likely larger sleep-apnea / HNS incumbents and distributors with stronger payer relationships, because every incremental reimbursement friction point makes physician behavior more conservative and lengthens the sales cycle. If Nyxoah’s guidance proves achievable, it still implies a much steeper second-half ramp than the current installed base would normally justify, so the market should watch whether reported account growth converts into recurring procedures rather than just authorizations. The real signal is not gross revenue, but cash conversion per active account.

The main risk is dilution, not demand. If management needs to raise within the next 6-9 months, the equity can underperform even on good operating prints because investors will anchor to post-financing per-share value rather than top-line momentum. Conversely, if reimbursement throughput improves faster than expected and the company delays financing until materially higher revenue, the stock can re-rate sharply because current valuation embeds very little execution success.

Consensus may be underestimating how much of the current debate is a timing question rather than a product question. The market is treating this as a binary product-market-fit story, but the better framing is a financing bridge trade: if the company can survive long enough to prove unit economics, upside is meaningful; if not, the equity gets diluted before the operating leverage is visible. That asymmetry argues for trading the balance-sheet milestone, not the revenue print alone.

Key Decisions for Investors

• Avoid outright long exposure in NYXH ahead of the next 1-2 quarters unless paired with a clear financing catalyst; the risk/reward is dominated by dilution timing rather than revenue trajectory.
• If long, use a call spread or small-size common position and treat any rally into financing speculation as an opportunity to reduce; upside is substantial if capital is raised after another step-up in U.S. traction, but downside is severe if the raise comes on weak terms.
• Consider a pair trade: long a stronger-funded medtech commercializer versus short NYXH to isolate execution/financing risk; the relative-value setup is better than a directionally bullish bet on the category.
• Set a hard review point after the next quarterly update: if active accounts and authorizations grow but cash burn remains unchanged, reduce immediately—this is the point where the market usually starts pricing a raise within 1-2 quarters.
• For event-driven traders, buy volatility rather than delta into financing/quarterly reporting windows; the stock’s path dependence is high, and implied downside from dilution can exceed any modest upside from an earnings beat.